KUALA LUMPUR: Supercomnet Technologies Bhd (STB) latest cathether for cardiovascular use has been approved by the US Food & Drug Administration (FDA).
The product, D*Clot HD Rotational Thrombectomy Catheter, is classified as a catheter or embolectomy on the FDA website and registered under STB's wholly-owned subsidiary Supercomal Medical Products Sdn Bhd (SMP), which principal activities involve the manufacturing and sub-assembly of cables for the medical device market.
STB in a statement today said with the FDA approval, the company can now start manufacturing the catheter for its client, which is Denmark-based company.
The latest development is in line with STB's push to expand into new markets and acquire new clients and diversify its corporate footprint globally.
At the same time, the company is also strive to solidify its position in current markets to achieve a leading original equipment manufacturer (OEM) spot in the automotive cable and medical device players, the statement noted.
STB is an ACE Market-listed company involved in manufacturing and assembling quality wires and cables for various segments such as medical devices, electronic appliances, consumer electronics and automotive.
For financial year (FY) 2019, STB posted a revenue of RM122.97 milion, representing an increase of 39.28 per cent year-on-year (yoy). Net profit rose 74 per cent yoy to RM19.38 million.
The major increase in turnover and profits was contributed by the increasing sales form existing customers of subsidiaries.
It is worth noting that several key products of SMP are utilised in critical medical devices that are needed in the treatment of Covid-19 patients.
Among the critical medical devices are disposable bronchoscopes, which are used in the first line of lung treatment for patients with suspected or confirmed Covid-19 infections, and the critical care monitoring cable that is presently being used for patients in the intensive care unit.